| 1 |
34459465 | Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. | 2022 Jan 1 |
1 |
| 2 |
35062934 | Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma. | 2022 Jan 21 |
1 |
| 3 |
35349331 | Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. | 2022 Jun 20 |
1 |
| 4 |
35460465 | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. | 2022 Apr 23 |
1 |
| 5 |
35532877 | FLT3-targeted treatment for acute myeloid leukemia. | 2022 May 9 |
2 |
| 6 |
35549749 | The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report. | 2022 May |
2 |
| 7 |
35565314 | Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. | 2022 Apr 27 |
1 |
| 8 |
35571528 | Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation. | 2022 |
1 |
| 9 |
35637252 | Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. | 2022 May 30 |
1 |
| 10 |
32753705 | Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation. | 2021 Jan |
1 |
| 11 |
32852395 | Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion. | 2021 May 1 |
2 |
| 12 |
33472354 | Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. | 2021 Mar 1 |
1 |
| 13 |
33514926 | Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience. | 2021 Jun |
1 |
| 14 |
33628103 | LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2021 |
1 |
| 15 |
33637883 | Correction to: Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience. | 2021 Jun |
1 |
| 16 |
33667419 | Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. | 2021 Jun |
1 |
| 17 |
34024909 | FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. | 2021 May 24 |
1 |
| 18 |
34341323 | Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. | 2021 Nov 1 |
1 |
| 19 |
34486940 | FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies. | 2021 Sep 6 |
4 |
| 20 |
34820336 | LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway. | 2021 |
3 |
| 21 |
34876631 | FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. | 2021 Dec 7 |
1 |
| 22 |
35071015 | Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. | 2021 |
1 |
| 23 |
31511612 | Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. | 2020 Feb |
1 |
| 24 |
32022292 | Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. | 2020 May |
1 |
| 25 |
32332018 | High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. | 2020 Aug 15 |
6 |
| 26 |
32373219 | Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. | 2020 |
1 |
| 27 |
32673171 | Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). | 2020 Sep 10 |
1 |
| 28 |
32697348 | Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. | 2020 Nov |
1 |
| 29 |
32791048 | Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. | 2020 Sep |
2 |
| 30 |
32882995 | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. | 2020 Sep 1 |
1 |
| 31 |
32984009 | First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. | 2020 |
1 |
| 32 |
33255818 | Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. | 2020 Nov 25 |
2 |
| 33 |
30270754 | FLT3 inhibitors in acute myeloid leukemia: Current and future. | 2019 Jan |
1 |
| 34 |
30514174 | Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia. | 2019 Dec |
1 |
| 35 |
30537918 | Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia. | 2019 Dec |
2 |
| 36 |
30681373 | Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. | 2019 Mar |
1 |
| 37 |
30792203 | Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. | 2019 Sep |
1 |
| 38 |
30898762 | Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. | 2019 Mar 26 |
2 |
| 39 |
31009704 | Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. | 2019 Aug |
1 |
| 40 |
31046582 | Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man. | 2019 May-Jun |
2 |
| 41 |
31122828 | Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. | 2019 Aug |
4 |
| 42 |
31203997 | Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia. | 2019 Jun |
3 |
| 43 |
31207705 | [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world]. | 2019 May 14 |
4 |
| 44 |
31237017 | Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. | 2019 Sep |
2 |
| 45 |
31243041 | Availability of FLT3 inhibitors: how do we use them? | 2019 Aug 29 |
1 |
| 46 |
31281512 | Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. | 2019 |
4 |
| 47 |
31310323 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. | 2019 Nov 1 |
3 |
| 48 |
31391334 | Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. | 2019 Aug 8 |
1 |
| 49 |
31418362 | [Effect of Low-Dose Triptolide and Sorafenib Alone and Their Combination on AML Cell Line MV411 and the Pathway of STAT5]. | 2019 Aug |
2 |
| 50 |
28876197 | The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients. | 2018 Apr |
1 |